Czech National Bank Increases Position in Insulet Co. (NASDAQ:PODD)

Czech National Bank raised its position in shares of Insulet Co. (NASDAQ:PODD) by 8.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,346 shares of the medical instruments supplier’s stock after buying an additional 1,060 shares during the period. Czech National Bank’s holdings in Insulet were worth $2,693,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Orion Portfolio Solutions LLC raised its position in shares of Insulet by 276.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock worth $2,069,000 after acquiring an additional 7,507 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Insulet by 349.3% during the 1st quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock worth $5,069,000 after buying an additional 22,993 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Insulet by 85.1% in the 4th quarter. Allianz Asset Management GmbH now owns 108,109 shares of the medical instruments supplier’s stock valued at $23,457,000 after buying an additional 49,715 shares in the last quarter. Duality Advisers LP grew its holdings in shares of Insulet by 89.4% during the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock worth $3,279,000 after purchasing an additional 9,029 shares during the last quarter. Finally, Diversify Advisory Services LLC acquired a new position in shares of Insulet in the 1st quarter valued at $1,043,000.

Analyst Ratings Changes

A number of equities analysts have commented on PODD shares. Redburn Atlantic began coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective for the company. Raymond James cut their target price on Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Canaccord Genuity Group restated a “buy” rating and issued a $234.00 price target on shares of Insulet in a research note on Tuesday, July 23rd. BTIG Research decreased their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group increased their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a report on Friday, May 10th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average price target of $232.13.

Insider Activity

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the sale, the director now owns 42,586 shares in the company, valued at approximately $7,703,807.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the sale, the senior vice president now directly owns 12,875 shares in the company, valued at approximately $2,574,485. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock worth $2,636,286 over the last ninety days. Corporate insiders own 0.47% of the company’s stock.

Insulet Trading Up 4.8 %

Shares of PODD traded up $8.79 during trading hours on Monday, hitting $190.98. The stock had a trading volume of 297,012 shares, compared to its average volume of 841,655. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $227.55. The firm has a market cap of $13.38 billion, a P/E ratio of 55.21, a P/E/G ratio of 3.53 and a beta of 1.16. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. The company’s fifty day simple moving average is $196.26 and its 200 day simple moving average is $183.78.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. During the same quarter in the previous year, the firm posted $0.38 EPS. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. Equities research analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.